Accelerate Diagnostics Inc. (AXDX) Trading Down 7.8%
Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares traded down 7.8% during mid-day trading on Tuesday . The company traded as low as $25.86 and last traded at $26.07, with a volume of 459,939 shares trading hands. The stock had previously closed at $28.29.
A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday. BTIG Research upgraded shares of Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a research report on Thursday, August 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.33.
The firm’s 50 day moving average price is $22.87 and its 200 day moving average price is $16.54. The company’s market cap is $1.33 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/accelerate-diagnostics-inc-axdx-trading-down-7-8.html
In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 90,147 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The shares were bought at an average cost of $13.95 per share, for a total transaction of $1,257,550.65. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 51.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Geneva Advisors LLC boosted its stake in shares of Accelerate Diagnostics by 3.6% in the second quarter. Geneva Advisors LLC now owns 27,180 shares of the company’s stock worth $391,000 after buying an additional 934 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Accelerate Diagnostics by 5.6% in the first quarter. Geode Capital Management LLC now owns 187,380 shares of the company’s stock worth $2,692,000 after buying an additional 9,910 shares during the last quarter. RTW Investments LLC boosted its stake in shares of Accelerate Diagnostics by 11.1% in the first quarter. RTW Investments LLC now owns 117,176 shares of the company’s stock worth $1,684,000 after buying an additional 11,708 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Accelerate Diagnostics during the first quarter worth approximately $1,019,000. Finally, Oaktop Capital Management II L.P. acquired a new stake in shares of Accelerate Diagnostics during the second quarter worth approximately $1,799,000. Institutional investors own 35.62% of the company’s stock.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.